Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02035670
Other study ID # TJHust-P1312
Secondary ID P131221
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 2014
Est. completion date December 2018

Study information

Verified date May 2018
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to determine whether two-step method of diagnostic strategy is effective in the diagnosis and treatment of fever of unknown origin (FUO). (TSMD research, a pilot study) Fever of unknown origin (FUO) is a fever in excess of 38.3◦C continued for more than 3 weeks, and its cause could not be identified by tests during hospitalization for more than 1 week [1]. As diagnostic techniques such as imaging technology and clinical tests have been developed and outpatient access to diagnostic tests have improved, the FUO is defined as a shortened period where the cause could not be revealed despite diagnostic tests during three visits to the outpatient department or during 3 days of hospitalization [2]. FUO can be caused by many diseases, and causes can vary depending on region and time period. FUO was first reported in the medical literature 80 years ago. Since then, the causative diseases have greatly changed with changes in the social environment and widespread use of diagnostic imaging. The causes of FUO, according to traditional diagnosis and treatment, could be divided into four principal groups: infections, non-infectious inflammatory diseases (NIID, including rheumatic diseases and vasculitic diseases), neoplasms, and other diseases. Despite the development of various diagnostic techniques, 34-51% of FUO patients remain undiagnosed [3,4]. In China, over-reliance on antibiotics for disease therapy and infection prevention are common phenomena in traditional treatment of FUO[5].

Two-step method of diagnostic strategy is a method to diagnose FUO disease. First step is to differentiate FUO according to the onset of disease and invasive pathogens. Second step is to further differentiate FUO according to trends of disease and inflammation scores. The diagnosis of FUO can be difficult for both patients and their physicians. Depending on the experience and qualifications of the treating physicians, time to reach a diagnosis can vary. Two-step method of diagnostic strategy would afford a standard method for physicians to diagnoses the FUO.

So many reports of FUO have also been published in China, but have been limited to single-facility or limited-region studies; no nationwide studies have yet been conducted. Moreover, few assessments of tests used in the diagnostic evaluation of FUO have been reported. In particular, few studies have assessed the clinical usefulness of tests such as serum procalcitonin or positron emission tomography (PET) in China, although these tests are now frequently used.

We therefore will conduct a multicenter collaborative retrospective and prospective (randomized and controlled )study of patients with FUO at hospitals affiliated with China's Ministry of Health. This is the first nationwide study in China on diseases causing FUO and the diagnostic workup, and identified diseases that should be considered when evaluating FUO in China. In addition, we will investigate the rate of performing various tests in the current diagnostic workup of FUO.

Classical FUO was diagnosed based on the definition by Durack et al[6] in patients meeting all of criteria 1-4 below.

1. Fever with axillary temperature ≥38°C at least twice over a ≥3-week period. 2. Unknown cause after three outpatient visits or during 3 days of hospitalization.

3. Not diagnosed with immunodeficiency before fever onset. 4. No confirmed HIV infection before fever onset. The data described below were collected. No additional testing was performed in this study due to insufficient data.

1. Patient characteristics: sex, age, concomitant disease, medical history and medication history.

2. Clinical findings: subjective symptoms and objective physical findings.

3. Blood tests: blood count, biochemical examination and inflammatory markers (C reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, etc.).

4. Results of blood cultures if performed.

5. Results of imaging studies and endoscopy if performed.

6. Results of cytology, histology, genetic testing or autopsy findings if performed.

7. Final diagnosis, day of diagnosis and outcome. This study is safety for no drug involved to determine the effectiveness of two-step method of diagnostic strategy in the diagnosis and treatment of fever of unknown origin.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 600
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of FUO

- Agreed to take part in this study

Exclusion Criteria:

- Diagnosed with immunodeficiency before fever onset.

- Confirmed HIV infection before fever onset.

- Hospitalized patients and hospital acquired infection cannot be ruled out

- Medical history of serious mental illness

- Medical history of severe seizures or using anticonvulsants currently

- Confirmed with HIV infection before fever onset or organ transplant patients, using glucocorticoid or immunsuppression or any other patients who are not considered to be suitable for this study

- having evidence of drug abuse or treat with methadone in the previous year

- included in other clinical trials

- unable or unwilling to provide informed consent or follow the request.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Two-step diagnostic strategy
The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive. The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive.

Locations

Country Name City State
China Huazhong University of Science and Technology,Tongji Medical College Affiliated Tongji Hospital Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Tongji Hospital

Country where clinical trial is conducted

China, 

References & Publications (5)

Bleeker-Rovers CP, Vos FJ, de Kleijn EM, Mudde AH, Dofferhoff TS, Richter C, Smilde TJ, Krabbe PF, Oyen WJ, van der Meer JW. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). 2007 Jan;86(1):26-38. — View Citation

Durack DT, Street AC. Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35-51. Review. — View Citation

PETERSDORF RG, BEESON PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961 Feb;40:1-30. — View Citation

Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnez A, Blockmans D, Bobbaers H. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med. 2003 May 12;163(9):1033-41. — View Citation

Xiao Y, Zhang J, Zheng B, Zhao L, Li S, Li L. Changes in Chinese policies to promote the rational use of antibiotics. PLoS Med. 2013 Nov;10(11):e1001556. doi: 10.1371/journal.pmed.1001556. Epub 2013 Nov 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary percentage of the FUO pateints being diagnosed correctly the patients discharged from hospital or after following of up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT02538770 - Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization N/A
Recruiting NCT05254522 - Fever of Unknown Orgin Registry in Internal Medicine Unit and Infectious Disease Units
Recruiting NCT04810351 - Fever of Unknown Origin (FUO) in Elderly Patients
Not yet recruiting NCT04073108 - Causes of FUO in Infants and Children
Completed NCT02084147 - PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases N/A
Recruiting NCT02618655 - Clinical Research for the Diagnosis of Tick-borne Diseases in Patients With Unexplained Acute Fever N/A
Recruiting NCT02196753 - PET CT in Suspected CIED Infection, a Pilot Study - PET Guidance I N/A
Enrolling by invitation NCT02695914 - Influence of Compound Qingre Granule on the Inflammatory Markers in Patient of FUO With Excess-heat Syndrome N/A
Completed NCT02544230 - Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia N/A
Withdrawn NCT04139395 - 68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO) Phase 3
Recruiting NCT05723185 - Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational Study
Completed NCT04851379 - PLACE OF THE 18F-FDG-PET/CT IN THE DIAGNOSTIC WORKUP IN PATIENTS WITH CLASSICAL FEVER OF UNKNOWN ORIGIN (FUO)
Completed NCT02786693 - Evaluation of Diagnosis of Fever and Biologic Inflammatory Syndrome of Unknown Origin